iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 65.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,599 shares of the company’s stock after selling 245,138 shares during the quarter. ADAR1 Capital Management LLC’s holdings in iTeos Therapeutics were worth $1,011,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after buying an additional 211,452 shares during the period. JPMorgan Chase & Co. increased its stake in shares of iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after purchasing an additional 5,368 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of iTeos Therapeutics by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock worth $2,268,000 after buying an additional 8,397 shares in the last quarter. Geode Capital Management LLC grew its holdings in iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after acquiring an additional 20,092 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of iTeos Therapeutics in the third quarter worth approximately $154,000. 97.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ITOS shares. Wells Fargo & Company cut their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. decreased their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock opened at $5.39 on Monday. The business has a 50-day simple moving average of $7.06 and a 200 day simple moving average of $8.06. iTeos Therapeutics, Inc. has a one year low of $5.32 and a one year high of $18.75. The firm has a market capitalization of $205.87 million, a price-to-earnings ratio of -1.71 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. On average, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.